Geek+, a provider of smart logistics solutions, has powered same-day delivery for Nike in Japan, providing advanced robotics solutions to Nike’s new distribution center in Chiba. The installation uses more than 200 robots from Geek+’s goods-to-person P series robot range.
Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that Tom Griffin has joined Nuvaira as Chief Financial Officer.
Tom Griffin has a 30-year track record of strong leadership guiding high-growth companies through investment financing, rapid commercialization growth and initial public offering stages. Tom was most recently Chief Financial Officer of Avedro, Inc. (NASDAQ: AVDR) a leading hybrid ophthalmic pharmaceutical and medical technology company.
According to the report, PerimeterX “leads the pack with robust machine learning and attack response capabilities.”
The report evaluated 13 vendors in the bot management market. PerimeterX received the highest ratings possible, in attack detection, attack response, threat research, feedback loops, performance metrics, vision, roadmap and market approach.
Read the report to learn more about why PerimeterX is a leader.
Singapore’s cross border startup Nium, formerly known as Instarem, is setting its sights on a New York Stock Exchange (NYSE) listing by 2022 and profitability by Q3 next year. In an interview with DealStreetAsia, Nium’s CEO and co-founder Prajit Nanu said the fintech company still has several “important indicators to fire” before hitting the IPO stage. By 2021-22, he hopes to earn the company a coveted spot on the NYSE.
Cymulate, the most comprehensive SaaS-based Breach and Attack Simulation (BAS) platform, today announced it has achieved 240% revenue growth in global 2019 new bookings compared to its strong, treble-growth performance of 2018. The company attains 91% customer retention and the number of employees has grown by over 220% over the last 12 months as operations extend across Europe and the US to support sales.
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced a second collaboration with Cancer Research UK, the world’s largest independent funder of cancer research, in which Cancer Research UK will fund and sponsor development of BT7401, a multivalent Bicycle CD137 agonist, through a Phase IIa clinical study.